LIVER: Taking out the JuNK to treat α1-antitrypsin deficiency

    loading  Checking for direct PDF access through Ovid

Abstract

New work has provided insight into the molecular pathways that underlie the liver disease that is associated with α1-antitrypsin deficiency, and has identified a novel approach to cell-based therapy.

Refers to Pastore, N. et al. Activation of JNK pathway aggravates proteotoxicity of hepatic mutant Z alpha1-antitrypsin. Hepatologyhttp://dx.doi.org/10.1002/hep.29035 (2017) | Baligar, P. et al. Bone marrow stem cell therapy partially ameliorates pathological consequences in livers of mice expressing mutant human α1-antitrypsin. Hepatologyhttp://dx.doi.org/10.1002/hep.29027 (2017)

Related Topics

    loading  Loading Related Articles